Ideaya Biosciences
Yahoo Finance • 5 days ago
Is IDEAYA Biosciences (IDYA) A Bargain Following Its ESMO 2026 Clinical Data?
IDEAYA Biosciences (IDYA) moved into focus after updated ESMO 2026 data for IDE849 in relapsed small cell lung cancer and neuroendocrine carcinomas, and for darovasertib in metastatic and primary uveal melanoma. Despite the fresh ESMO hea... Full story
Yahoo Finance • 15 days ago
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
CHICAGO, October 21, 2026--(BUSINESS WIRE)--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm's continued expansion of its biotech offering. Young join... Full story
Yahoo Finance • last month
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the promotion o... Full story
Yahoo Finance • 2 months ago
Biotech Breakout: What's in focus after Moderna's cancer win?
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story
Yahoo Finance • 3 months ago
The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership
IDEAYA Biosciences recently reported a second-quarter 2026 net loss of US$112.45 million, or US$1.22 per basic and diluted share, while also disclosing a wider six‑month loss versus the prior year. In parallel, IDEAYA advanced its precisio... Full story
Yahoo Finance • 3 months ago
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion e... Full story
Yahoo Finance • 5 months ago
IDEAYA's Board Of Directors Elect Hata As Chairman Of Board
(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), a clinical-stage oncology company, on Tuesday announced the appointment of Yujiro S. Hata as Chairman of the Board by its Board of Directors. Hata currently serves as the President and Chief Ex... Full story
Yahoo Finance • 5 months ago
Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study
IDEAYA Biosciences Inc. (NASDAQ:IDYA) is one of the 10 best AI driven biotech stocks to invest in. On June 3, in order to study the safety and efficacy of IDE892 in conjunction with Roche’s pan-RAS inhibitor, RG6505, in patients with MTAP... Full story
Yahoo Finance • 5 months ago
Biggest stock movers Tuesday: APLD, QCOM, and more
[glowing graph 2] Jonathan Kitchen Stock futures rose slightly, and crude oil benchmark prices fell on Tuesday morning as geopolitical anxieties showed signs of easing. Here are some of Tuesday's biggest stock movers: BIGGEST STOCK GAIN... Full story
Yahoo Finance • 5 months ago
What IDEAYA Biosciences (IDYA)'s Darovasertib Phase 2/3 Win and Roche Deal Mean For Shareholders
IDEAYA Biosciences recently reported full Phase 2/3 OptimUM-02 data showing its darovasertib and crizotinib combination improved progression-free survival and response rates versus standard therapies in first-line HLA*A2:01 negative metast... Full story
Yahoo Finance • 5 months ago
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutan... Full story
Yahoo Finance • 6 months ago
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation at ASCO IDEAYA to initiate RTOR submission process with first pre-submiss... Full story
Yahoo Finance • 6 months ago
Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?
Is IDYA a good stock to buy? We came across a bullish thesis on IDEAYA Biosciences, Inc. on Valueinvestorsclub.com by pestopenguin. In this article, we will summarize the bulls’ thesis on IDYA. IDEAYA Biosciences, Inc.'s share was trading... Full story
Yahoo Finance • 7 months ago
Stocks Settle Higher in Hopes for an Agreement to End the Iran War
The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.02%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.63%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.06%. June E-mini S&P futures (ESM26) rose +0.98%, and June E-m... Full story
Yahoo Finance • 7 months ago
Stocks Recover as Oracle Leads Software Companies Higher
The S&P 500 Index ($SPX) (SPY) today is up +0.09%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.39%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.16%. June E-mini S&P futures (ESM26) are up +0.12%, and June E-mini Nasdaq f... Full story
Yahoo Finance • 7 months ago
Stocks Mixed as US Set to Blockade the Strait of Hormuz
The S&P 500 Index ($SPX) (SPY) today is up +0.05%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.39%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.21%. Stock indexes are mixed this morning even as crude oil prices surge aft... Full story
Yahoo Finance • 7 months ago
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
SOUTH SAN FRANCISCO, Calif., April 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pre-market press release and host a confe... Full story
Yahoo Finance • 7 months ago
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and ~350-to-2,000-fold selectivity over the KAT5 and K... Full story
Yahoo Finance • 7 months ago
Uveal Neoplasms Markets, Companies, and Investment Opportunities Analysis 2026-2030
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Uveal Neoplasms Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global uveal neoplasms market has demonstrated robust growth, with projections indicating a ri... Full story
Yahoo Finance • 7 months ago
IDEAYA slips on delaying results from darovasertib uveal melanoma trial
[Close up of the eye with carcinoma] flik47/iStock via Getty Images * IDEAYA Biosciences (IDYA [https://seekingalpha.com/symbol/IDYA]) is down ~5% in Monday trading after announcing it is delaying the release of topline results from a p... Full story